Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine—Navi Mumbai, India, 2018

Author:

Date Kashmira1,Shimpi Rahul2,Luby Stephen3,N Ramaswami4,Haldar Pradeep5,Katkar Arun2,Wannemuehler Kathleen1,Mogasale Vittal6,Pallas Sarah1,Song Dayoung6,Kunwar Abhishek2,Loharikar Anagha1,Yewale Vijay7,Ahmed Danish2,Horng Lily3,Wilhelm Elisabeth1,Bahl Sunil8,Harvey Pauline2,Dutta Shanta9,Bhatnagar Pankaj2

Affiliation:

1. Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

2. World Health Organization, India Country Office, New Delhi, India

3. Stanford University, Stanford, California, USA

4. Navi Mumbai Municipal Corporation, Navi Mumbai, India

5. Ministry of Health and Family Welfare, Government of India, India

6. International Vaccine Institute, Republic of Korea

7. Dr. Yewale Multispecialty Hospital, Navi Mumbai, India

8. World Health Organization, Regional Office for South-East Asia, New Delhi, India

9. National Institute of Cholera and Enteric Diseases–Indian Council for Medical Research, Kolkata, India

Abstract

Abstract Background Typhoid fever prevention and control efforts are critical in an era of rising antimicrobial resistance among typhoid pathogens. India remains one of the highest typhoid disease burden countries, although a highly efficacious typhoid conjugate vaccine (TCV), prequalified by the World Health Organization in 2017, has been available since 2013. In 2018, the Navi Mumbai Municipal Corporation (NMMC) introduced TCV into its immunization program, targeting children aged 9 months to 14 years in 11 of 22 areas (Phase 1 campaign). We describe the decision making, implementation, and delivery costing to inform TCV use in other settings. Methods We collected information on the decision making and campaign implementation in addition to administrative coverage from NMMC and partners. We then used a microcosting approach from the local government (NMMC) perspective, using a new Microsoft Excel–based tool to estimate the financial and economic vaccination campaign costs. Results The planning and implementation of the campaign were led by NMMC with support from multiple partners. A fixed-post campaign was conducted during weekends and public holidays in July–August 2018 which achieved an administrative vaccination coverage of 71% (ranging from 46% in high-income to 92% in low-income areas). Not including vaccine and vaccination supplies, the average financial cost and economic cost per dose of TCV delivery were $0.45 and $1.42, respectively. Conclusion The first public sector TCV campaign was successfully implemented by NMMC, with high administrative coverage in slums and low-income areas. Delivery cost estimates provide important inputs to evaluate the cost-effectiveness and affordability of TCV vaccination through public sector preventive campaigns.

Funder

Centers for Disease Control and Prevention

World Health Organization

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3